137442-18-3

Basic information

• Product Name: 2,4(1H,3H)-Pyrimidinedione,5-fluoro-3-(hydroxymethyl)-(9CI)
• Synonyms: 2,4(1H,3H)-Pyrimidinedione,5-fluoro-3-(hydroxymethyl)-(9CI)
• CAS NO: 137442-18-3
• Molecular Formula: C5H5FN2O3
• Molecular Weight: 160.1032032
• Product Categories: HALIDE
• Mol File: 137442-18-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2,4(1H,3H)-Pyrimidinedione,5-fluoro-3-(hydroxymethyl)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4(1H,3H)-Pyrimidinedione,5-fluoro-3-(hydroxymethyl)-(9CI)(137442-18-3)
• EPA Substance Registry System: 2,4(1H,3H)-Pyrimidinedione,5-fluoro-3-(hydroxymethyl)-(9CI)(137442-18-3)

Safety Data

• Hazardous Substances Data: 137442-18-3(Hazardous Substances Data)

Upstream product

• 50-00-0 formaldehyd 
• 51-21-8 5-fluorouracil 

Relevant articles and documents

Drug delivery to tumours using a novel 5-FU derivative encapsulated into lipid nanocapsules

In this work, a novel lipophilic 5-fluorouracil (5-FU) derivative was synthesised and encapsulated into lipid nanocapsules (LNC). 5-FU was modified with lauric acid to give a lipophilic mono-lauroyl-derivative (5-FU-C12, MW of about 342 g/mol, yield of reaction 70%). 5-FU-C12 obtained was efficiently encapsulated into LNC (encapsulation efficiency above 90%) without altering the physico-chemical characteristics of LNC. The encapsulation of 5-FU-C12 led to an increased stability of the drug when in contact with plasma being the drug detectable until 3 h following incubation. Cytotoxicity assay carried out using MTS on 2D cell culture showed that 5-FU-C12-loaded LNC had an enhanced cytotoxic effect on glioma (9L) and human colorectal (HTC-116) cancer cell line in comparison with 5-FU or 5-FU-C12. Then, HCT-116 tumour spheroids were cultivated and the reduction of spheroid volume was measured following treatment with drug-loaded LNC and drugs alone. Similar reduction on spheroids volume was observed following the treatment with drug-loaded LNC, 5-FU-C12 and 5-FU alone, while blank LNC displayed a reduction in cell viability only at high concentration. Globally, our data suggest that the encapsulation increased the activity of the 5-FU-C12. However, in-depth evaluations of LNC permeability into spheroids are needed to disclose the potential of these nanosystems for cancer treatment.

DRUG FORMULATIONS FOR CANCER TREATMENT

Compounds and pharmaceutical formulations containing these compounds are described. Also described are methods of making and using the compounds. The compounds include nucleobases, nucleobase analogues, or combinations thereof. In one embodiment, a nucleobase analogue is combined with doxorubicin and encapsulated within a liposome for use in inhibiting or preventing the growth of cancer cells. Further described are pharmaceutical compositions containing two or more therapeutically active agents encapsulated within a vesicle, such as a liposome, wherein the molar ratio of the agents provides a synergistic therapeutic effect.

N-hydroxymethyl derivatives of nitrogen heterocycles as possible prodrugs I: N-hydroxymethylation of uracils

-